TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
NCT00386412
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
132
Enrollment
OTHER
Sponsor class
Conditions
Cytomegalovirus Infection
Interventions
DRUG:
Valganciclovir
Sponsor
PETHEMA Foundation